421 related articles for article (PubMed ID: 26755635)
81. APOBEC3B, a molecular driver of mutagenesis in human cancers.
Zou J; Wang C; Ma X; Wang E; Peng G
Cell Biosci; 2017; 7():29. PubMed ID: 28572915
[TBL] [Abstract][Full Text] [Related]
82. Replication catastrophe induced by cyclic hypoxia leads to increased APOBEC3B activity.
Bader SB; Ma TS; Simpson CJ; Liang J; Maezono SEB; Olcina MM; Buffa FM; Hammond EM
Nucleic Acids Res; 2021 Jul; 49(13):7492-7506. PubMed ID: 34197599
[TBL] [Abstract][Full Text] [Related]
83. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
bioRxiv; 2023 Aug; ():. PubMed ID: 37577595
[TBL] [Abstract][Full Text] [Related]
84. Evidence for APOBEC3B mutagenesis in multiple human cancers.
Burns MB; Temiz NA; Harris RS
Nat Genet; 2013 Sep; 45(9):977-83. PubMed ID: 23852168
[TBL] [Abstract][Full Text] [Related]
85. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
[TBL] [Abstract][Full Text] [Related]
86. Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes.
Adler N; Bahcheli AT; Cheng KCL; Al-Zahrani KN; Slobodyanyuk M; Pellegrina D; Schramek D; Reimand J
Sci Adv; 2023 Nov; 9(44):eadh3083. PubMed ID: 37922356
[TBL] [Abstract][Full Text] [Related]
87. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma.
Cannataro VL; Kudalkar S; Dasari K; Gaffney SG; Lazowski HM; Jackson LK; Yildiz I; Das RK; Gould Rothberg BE; Anderson KS; Townsend JP
Lung Cancer; 2022 Sep; 171():34-41. PubMed ID: 35872531
[TBL] [Abstract][Full Text] [Related]
88. Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.
Romani B; Engelbrecht S; Glashoff RH
Arch Virol; 2009; 154(10):1579-88. PubMed ID: 19669862
[TBL] [Abstract][Full Text] [Related]
89. Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Isozaki H; Sakhtemani R; Abbasi A; Nikpour N; Stanzione M; Oh S; Langenbucher A; Monroe S; Su W; Cabanos HF; Siddiqui FM; Phan N; Jalili P; Timonina D; Bilton S; Gomez-Caraballo M; Archibald HL; Nangia V; Dionne K; Riley A; Lawlor M; Banwait MK; Cobb RG; Zou L; Dyson NJ; Ott CJ; Benes C; Getz G; Chan CS; Shaw AT; Gainor JF; Lin JJ; Sequist LV; Piotrowska Z; Yeap BY; Engelman JA; Lee JJ; Maruvka YE; Buisson R; Lawrence MS; Hata AN
Nature; 2023 Aug; 620(7973):393-401. PubMed ID: 37407818
[TBL] [Abstract][Full Text] [Related]
90. Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.
Yamazaki H; Shirakawa K; Matsumoto T; Hirabayashi S; Murakawa Y; Kobayashi M; Sarca AD; Kazuma Y; Matsui H; Maruyama W; Fukuda H; Shirakawa R; Shindo K; Ri M; Iida S; Takaori-Kondo A
Sci Rep; 2019 May; 9(1):7122. PubMed ID: 31073151
[TBL] [Abstract][Full Text] [Related]
91. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma.
Cannataro VL; Gaffney SG; Sasaki T; Issaeva N; Grewal NKS; Grandis JR; Yarbrough WG; Burtness B; Anderson KS; Townsend JP
Oncogene; 2019 May; 38(18):3475-3487. PubMed ID: 30647454
[TBL] [Abstract][Full Text] [Related]
92. Efficient base editing in methylated regions with a human APOBEC3A-Cas9 fusion.
Wang X; Li J; Wang Y; Yang B; Wei J; Wu J; Wang R; Huang X; Chen J; Yang L
Nat Biotechnol; 2018 Nov; 36(10):946-949. PubMed ID: 30125268
[TBL] [Abstract][Full Text] [Related]
93. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
[TBL] [Abstract][Full Text] [Related]
94. APOBEC1 cytosine deaminase activity on single-stranded DNA is suppressed by replication protein A.
Wong L; Vizeacoumar FS; Vizeacoumar FJ; Chelico L
Nucleic Acids Res; 2021 Jan; 49(1):322-339. PubMed ID: 33330905
[TBL] [Abstract][Full Text] [Related]
95. APOBEC-mediated editing of viral RNA.
Bishop KN; Holmes RK; Sheehy AM; Malim MH
Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
[TBL] [Abstract][Full Text] [Related]
96. Activation-induced cytidine deaminase acts on double-strand breaks in vitro.
Shen HM
Mol Immunol; 2007 Feb; 44(5):974-83. PubMed ID: 16697045
[TBL] [Abstract][Full Text] [Related]
97. Reward versus risk: DNA cytidine deaminases triggering immunity and disease.
Pham P; Bransteitter R; Goodman MF
Biochemistry; 2005 Mar; 44(8):2703-15. PubMed ID: 15723516
[TBL] [Abstract][Full Text] [Related]
98. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases.
Shi R; Wang X; Wu Y; Xu B; Zhao T; Trapp C; Wang X; Unger K; Zhou C; Lu S; Buchner A; Schulz GB; Cao F; Belka C; Su C; Li M; Shu Y
Theranostics; 2022; 12(9):4181-4199. PubMed ID: 35673559
[No Abstract] [Full Text] [Related]
99. Patterns and processes of somatic mutations in nine major cancers.
Jia P; Pao W; Zhao Z
BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
[TBL] [Abstract][Full Text] [Related]
100. Learning mutational signatures and their multidimensional genomic properties with TensorSignatures.
Vöhringer H; Hoeck AV; Cuppen E; Gerstung M
Nat Commun; 2021 Jun; 12(1):3628. PubMed ID: 34131135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
